TTOO Stock Price: T2 Biosystems Inc plummets following earnings report
|- NASDAQ:TTOO sinks 10.95% on Tuesday amidst quarterly earnings call.
- The diagnostics firm has been in the news lately for its COVID-19 panel for virus detection.
NASDAQ:TTOO dropped throughout the trading session on Tuesday, as nervous investors sold off before the earnings call after the closing bell. T2 shareholders have enjoyed a profitable run thus far as the stock has risen by over 125% during the last year. Shares have also increased by 35% over the past month – making this last-minute pullback in the stocks price a reversal of the otherwise bullish momentum the company has seen.
T2 Biosystems has been a fixture on penny stock investors’ radar after the diagnostics company announced that it had developed a molecular diagnostics test for detecting the coronavirus in patients via a nasopharyngeal swab. The sample swab is then analyzed with near 100% results available within two hours. As America continues to struggle with containing COVID-19 we should see companies like T2 Biosystems remain relevant for the rest of 2020 and well into 2021 if the virus lingers.
T2 Biosystems Stock
T2 Biosystems reported a 74.29% increase in earnings per share for this quarter as well as a 41.46% year-over-year increase in revenues. Still, it is difficult to gauge how well TTOO is currently being managed as a quick glance at their financials should give investors pause. T2 Biosystems currently sports an EBITDA of $-49.2 million, an operating margin of -572.40%, and a return on assets of -60.87%. These are several key indicators of poor management and a company that just isn’t profitable. TTOO’s board of directors recently vetoed a proposed reverse stock split that would have diluted the penny stock’s price quite a bit – just another sign that the company is financially unhealthy.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.